Another problem is that modeling studies, like this one, are inherently less powerful than other
kinds of medical research: randomized
clinical trials, the gold
standard in medical research, in which patients are randomly assigned different treatments or no treatment; case - control studies, which compare patients who have a condition with those who do not; or cohort studies, which determine the risk
of contracting a disease by studying a group
of people with similar demographics.
The drug, a monoclonal antibody called ipilimumab, is the first treatment
of any
kind ever shown in a large, randomized phase III
clinical study (study MDX010 - 20) to improve overall survival in patients with metastatic melanoma who no longer respond to
standard therapy.